In health, the glucose concentration of airway surface liquid (ASL) is 0.4 mM, about 12 times lower than the blood glucose concentration. Airway glucose homeostasis comprises a set of processes that actively maintain low ASL glucose concentration against the transepithelial gradient. Tight junctions between airway epithelial cells restrict paracellular glucose movement. Epithelial cellular glucose transport and metabolism removes glucose from ASL. Low ASL glucose concentrations make an important contribution to airway defense against infection, limiting bacterial growth by restricting nutrient availability. Both airway inflammation, which increases glucose permeability of tight junctions, and hyperglycemia, which increases the transepithelial glucose gradient, increase ASL glucose concentrations, with the greatest effect seen where they coexist. Elevated ASL glucose drives proliferation of bacteria able to use glucose as a carbon source, including Staphylococcus aureus, Pseudomonas aeruginosa, and other gram-negative bacteria. Clinically, this appears to be important in driving exacerbations of chronic lung disease, especially in patients with comorbid diabetes mellitus. Drugs can restore airway glucose homeostasis by reducing the permeability of tight junctions (eg, metformin), increasing epithelial cell glucose transport (eg, b-agonists, insulin), and/or by lowering blood glucose (eg, dapagliflozin). In cell culture and animal models these reduce ASL glucose concentrations and limit bacterial growth, preventing infection. Observational studies in humans indicate that airway glucose homeostasis-modifying drugs could prevent chronic lung disease exacerbations if tested in randomized trials.
lung lumen, promoting bacterial growth. As bacteria vary in their ability to use different nutrient sources this causes differential growth, altering the composition of the microbial community and driving inflammation and injury. In this review, we consider the role of glucose homeostasis in restricting nutrient availability in the airway. We explore factors that disrupt airway glucose homeostasis and review the impact of these in promoting bacterial growth and infection. We present evidence that drugs that restore glucose homeostasis reduce bacterial growth in the airway and examine the clinical potential of these new therapies in the prevention and treatment of pulmonary infection.
Glucose Homeostasis and the Lung
In health, glucose concentrations in fluid lining the airway epithelial surface (airway surface liquid, ASL) are maintained at approximately 0.4 mM, despite a strong transepithelial gradient for movement of glucose from the blood (4.9-6.1 mM glucose). 2 The principal mechanisms limiting ASL glucose concentrations include epithelial tight junctions, and glucose transport and metabolism (Fig 2) .
Tight junctions in airway epithelium are made up of proteins including junctional adhesion molecules, claudins, and occludins, which are linked to cytoskeletal proteins and each other by scaffolding proteins such as zonula occludens. These junctions generally preclude paracellular movement. However, the junctions contain pore and leak pathways, determined by the abundance and localization of constituent proteins, which allow paracellular diffusion of selected molecules. 3 Airway epithelial tight junctions are poorly permeable to glucose, although some paracellular glucose diffusion into ASL occurs. 4, 5 The pathways by which glucose crosses the tight junctions are currently unknown. However, claudin 1 and occludin appear to be important in determining tight junction glucose permeability in cultured airway epithelial cell monolayers. 6 In the airway epithelium, the predominant glucose transporters expressed are facilitative glucose transporters (GLUTs). These allow passive diffusion of glucose across cell membranes, driven by a gradient generated by rapid intracellular glucose metabolism. GLUTs are expressed in both apical (lumen-facing) and basolateral (blood/interstitium-facing) airway epithelial cell membranes. GLUT-mediated glucose uptake across the apical membrane directly reduces glucose concentrations in ASL. Uptake across the basolateral membrane may modify local glucose concentrations, reducing glucose concentration gradients for movement of glucose into ASL. 4, 5 In the distal lung, sodiumcoupled glucose transporter isoform 1 (SGLT1) predominates in alveolar luminal membranes and drives glucose clearance from ASL by utilizing both intracellular glucose and sodium ion-driven gradients. lipopolysaccharide. 13 In cultured airway epithelial cell monolayers, P aeruginosa infection reduced the abundance of tight junction proteins claudin 1 and occludin between the cells and induced the appearance of occludin cleavage fragments. 6 This was associated with an increase in paracellular glucose flux. It is worth noting that, in epithelial cell monolayers, inflammation also increased the abundance of GLUTs and GLUTmediated glucose uptake. 12 Although this was insufficient to prevent a rise in ASL glucose concentrations, it raises the interesting possibility that dynamic regulation of GLUTs could mitigate the increased flux of glucose into ASL during inflammation.
Hyperglycemia
People with diabetes mellitus have increased nasal (4 [2] [3] [4] [5] [6] [7] chestjournal.org other gram-negative bacteria. In humans this is associated with clinical infections, including rhinosinusitis and exacerbations of chronic lung disease.
Airway Epithelial Cell-Bacterial Cocultures
Apical growth of S aureus and P aeruginosa increases when basolateral glucose concentrations are elevated in cocultures using a variety of glucose concentrations, cell types, and bacterial strains. 5, 13, 14 The effect of elevating basolateral glucose on apical bacterial growth can be replicated by pharmacologic blockade of GLUT transport. 5 It can be prevented by substituting L-glucose (a nonmetabolizable, nontransportable glucose analog) for D-glucose 14 or using bacteria with mutated carbohydrate transport genes. 16 Taken together, these findings indicate that elevated ASL glucose is directly causing the observed increase in bacterial growth.
Animal Models
In mouse and rat models of respiratory infection, diabetes mellitus is associated with increased pulmonary bacterial growth irrespective of rodent species (mice or rats), form of diabetes (leptin receptor deficient [db/db], leptin deficient [ob/ob], streptozotocin-or alloxan-induced), or bacterial species (S aureus or P aeruginosa). 5, 13, [18] [19] [20] As in coculture models, elevated glucose concentrations in lung secretions appear directly to stimulate bacterial growth. Increased pulmonary proliferation of P aeruginosa in diabetic mouse lungs is dependent on its ability to use glucose as a nutrient source and does not occur with mutant bacterial strains from which glucose uptake and utilization genes have been deleted. 5 In diabetic rats, pulmonary proliferation of P aeruginosa was inhibited by isoproterenol, which stimulates glucose removal from ASL, and promoted by pharmacologic inhibition of SGLT1. 
Restoration of Airway Glucose Homeostasis
Where airway glucose homeostasis is disrupted by hyperglycemia and/or inflammation, drugs that reduce epithelial tight junction permeability, increase epithelial glucose transport, and/or reduce blood glucose concentrations can restore homeostasis and restrict the availability of glucose as a nutrient source (Fig 3) . This reduces bacterial growth in experimental models and has therapeutic potential in the prevention and treatment of pulmonary infections in humans.
Epithelial Tight Junctions
Metformin: Metformin, a biguanide, is the drug that has been most extensively studied in this context. It is an insulin sensitizer that exerts at least some of its actions through activation of AMP-activated protein kinase (AMP-kinase). In airway epithelium, metformin is antiinflammatory 36 and reduces permeability by altering tight junction protein expression (discussed below). As it also lowers blood glucose in people with type 2 diabetes, 37 although slowly over weeks rather than days, it thus has several beneficial effects on airway glucose homeostasis.
In epithelial cell monolayers, metformin increased transepithelial electrical resistance in an AMP-kinasedependent manner 13 and increased expression of the tight junction proteins claudin 1 and occludin. 6 Metformin reduced the rise in ASL glucose concentrations caused by raising basolateral glucose from 10 to 40 mM by approximately 50%. 13 In epithelial cell-bacterial coculture models, metformin pretreatment ameliorated both S aureus-induced 13 and P aeruginosainduced 6 increases in paracellular glucose permeability and limited the occludin cleavage and reduction in claudin 1 abundance seen with P aeruginosa. In animal models, 3 days of metformin treatment reduced lung glucose concentrations (BAL) in diabetic mice to the level seen in nondiabetic mice, without altering blood glucose concentrations. 18 Metformin reduced glucose flux across mouse trachea, indicating that reduced epithelial tight junction permeability was a contributing mechanism. 13 The restriction in ASL glucose concentrations seen with metformin is associated with a reduction in bacterial growth at the epithelial surface. In airway epithelial cell monolayers, metformin pretreatment inhibited the apical growth of S aureus 13 and P aeruginosa 14 in a dose-dependent manner and prevented the increase in bacterial growth usually induced by increasing basolateral glucose concentrations. In diabetic mice, metformin pretreatment reduced pulmonary proliferation of S aureus 13 and P aeruginosa 18 to levels seen in nondiabetic animals, despite having no effect on blood glucose.
Other Candidates: In airway epithelial cell monolayers, glucocorticoids, 38 1,25-dihydroxyvitamin D 3 , 39 peroxisome proliferator-activated receptor g (PPARg)
agonists, 40 and azithromycin 41 have all been shown to increase expression of tight junction proteins and reduce epithelial permeability to ions and/or dextran. Azithromycin and vitamin D pretreatment prevented the reduction in transepithelial resistance and tight junction protein rearrangement induced by inflammatory stimuli (P aeruginosa or toluene diisocyanate, respectively). 39, 42 Insulin has recently been shown to promote airway barrier function, increasing transepithelial electrical resistance and reducing paracellular flux of small molecules. 43 While all these drugs have potential to restrict movement of glucose into the ASL, limiting its availability to bacteria as a nutrient source, to our knowledge this has not been tested. chestjournal.org kinase A pathway. In rat distal lung, isoproterenol increased translocation of SGLT1 to the luminal membrane. 19 In diabetic rats, this was associated with a 50% reduction in the glucose concentration of BAL. In vitro, proliferation of MRSA and P aeruginosa was reduced by 30% to 40% in BAL from diabetic rats pretreated with isoproterenol compared with BAL from rats pretreated with saline. Similarly, isoproterenol pretreatment reduced in vivo proliferation of P aeruginosa in diabetic rat lungs.
Insulin: A recent study in primary human airway epithelial cells found that insulin treatment stimulated cellular glucose uptake. 43 This was inhibited by cytochalasin B, consistent with a requirement for GLUT translocation to the cell membrane. Glucose uptake across airway epithelial cell monolayers is also stimulated by treatment with proinflammatory mediators. These induced increased expression of GLUTs and increased GLUT-mediated glucose uptake across apical cell membranes. 12 The mechanism underlying inflammation-induced up-regulation of GLUTs in airway epithelium has not been identified, but this represents a potential target for new treatments to lower ASL glucose concentrations.
Blood Glucose Control
Sodium-Coupled Glucose Transporter Isoform 2 Inhibitors: This relatively new class of antidiabetic drugs lowers blood glucose by inhibiting glucose reabsorption in the renal tubules, resulting in increased glucose excretion in the urine. They reduce ASL glucose concentration by reducing the gradient for movement of glucose from blood into ASL. As these drugs are highly selective for SGLT2 over SGLT1, they do not directly affect glucose transport in the lung. 17 In diabetic mice, 4 days of treatment with the SGLT2 inhibitor dapagliflozin significantly reduced blood (from 21.6 AE 19 to 11.4 AE 0.7 mM) and BAL (from 0.28 AE 0.15 to 0.15 AE 0.01 mM) glucose concentrations. 17 In mice infected with P aeruginosa, bacterial counts at 24 h were twice as high in BAL from diabetic as from nondiabetic mice. Pretreatment of diabetic mice with dapagliflozin for 7 days before infection reduced bacterial counts in BAL from diabetic mice to levels seen in nondiabetic mice. 17 
Mixed Mechanisms
Many of the drugs listed previously have potential to lower ASL glucose concentrations by more than one mechanism. Metformin, PPARg agonists, and insulin all lower blood glucose concentrations, reducing the transepithelial gradient for movement of glucose into ASL. PPARg agonists may also increase intracellular glucose metabolism, increasing local gradients for glucose uptake from ASL into airway epithelial cells.
Clinical Potential
In experimental models, drugs that modify airway glucose homeostasis restrict availability of glucose in airway secretions, reducing bacterial proliferation. The next step in developing this new therapeutic approach is to test the ability of these drugs to prevent, or augment treatment, of pulmonary infection in humans. Observational studies and a few small clinical trials in humans support this approach.
In people with chronic lung disease and diabetes, those taking metformin or thiazolidinediones had fewer respiratory infections than those taking other medication. Patients with asthma and diabetes taking metformin had a fivefold lower risk of asthma-related hospitalization and a two-to threefold lower risk of any exacerbation. 44 Patients with COPD and diabetes taking thiazolidinediones had a 14% reduction in the number of exacerbations compared with those taking alternative oral antihypoglycemics. 45 In people with CF with diabetes or prediabetes, several small clinical trials have shown that insulin treatment reduced annual exacerbation rates by two-to threefold.
46,47

Conclusions
Airway glucose homeostasis plays an important role in restricting nutrient availability in the lung lumen. Where this is disrupted by inflammation or hyperglycemia, ASL glucose concentrations increase. This "nutrient imbalance" promotes the proliferation of bacteria able to use glucose as a carbon source such as S aureus, P aeruginosa, and other gram-negative bacteria, driving infection. Drugs that restore airway glucose homeostasis can reduce bacterial proliferation, promoting elimination of bacteria by the immune system and preventing or augmenting treatment of infection. Observational studies in humans indicate that antidiabetic drugs that modify airway glucose homeostasis could be better at preventing respiratory infection than those that only lower blood glucose. Airway glucose homeostasis modifiers could also prevent infection in people with chronic lung disease who have normal or impaired glucose tolerance not requiring antidiabetic medication. Metformin and dapagliflozin have the best supporting experimental evidence of potential benefit as modifiers of airway glucose homeostasis and now need to be tested separately and in combination in clinical trials to determine the efficacy of this approach in the prevention of respiratory infection.
